NARKOSEFORMULIERUNG

European patent · EP2525798 · In force

Register entry

Publication number
EP2525798
Application number
EP11734245
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 19, 2011
Published
Nov 28, 2012
Granted
Aug 9, 2017
Protection ends at the latest
Jan 18, 2031
Next annual fee due
Jan 31, 2027
IPC classes
A61K 31/56 (2006.01)
A61K 47/40 (2006.01)
A61K 31/57 (2006.01)
A61P 23/00 (2006.01)
Priority
US 385318 P 22.09.2010
US 297249 P 21.01.2010
PCT application
PCT/AU2011/000050 19.01.2011
PCT publication
WO2011/088503 28.07.2011
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  3. Feb 1, 2024

    Change

    Published in Swissreg on 01.02.2024

  4. Jul 14, 2023

    Change

    Published in Swissreg on 14.07.2023

  5. Aug 9, 2022

    Change

    Published in Swissreg on 09.08.2022

  6. Sep 22, 2021

    Transferred

    Owner
    Drawbridge Pharmaceuticals Pty Ltd., Level 33, 360 Collins Street, Melbourne VIC 3000, Australia → Drawbridge Pharmaceuticals Pty Ltd., 23 Milton Parade, Malvern VIC 3144, Australia

    Published in Swissreg on 22.09.2021

  7. Aug 9, 2017

    Granted

    Published in Swissreg on 09.08.2017

Parties

Holder

Drawbridge Pharmaceuticals Pty Ltd.

23 Milton Parade, Malvern VIC 3144, AU

Inventor

GOODCHILD, Juliet Marguerite

Malvern Victoria 3144, AU

GOODCHILD, Colin Stanley

Malvern Victoria 3144, AU

BOYD, Benjamin James

Warrandyte Victoria 3113, AU

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.